ストックスクリーナーアプリを入手
297.69
1.89%
5.53
アフターアワーズ：
298.00
0.31
+0.10%
前日終値:
$292.16
開ける：
$297.31
24時間の取引高:
1.26M
Relative Volume:
1.14
時価総額：
$39.75B
収益：
$4.29B
当期純損益:
$577.22M
株価収益率:
70.73
EPS:
4.2086
ネットキャッシュフロー:
$641.34M
1週間 パフォーマンス:
+4.04%
1か月 パフォーマンス:
+0.89%
6か月 パフォーマンス:
-28.30%
1年 パフォーマンス:
-2.08%
1日の値動き範囲:
$293.97
$302.85
1週間の範囲:
$283.10
$310.53
52週間の値動き範囲:
$283.10
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
名前
Alnylam Pharmaceuticals Inc
セクター
電話
(617) 551-8200
住所
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
297.69 | 39.01B | 4.29B | 577.22M | 641.34M | 4.2086 |
VRTX
Vertex Pharmaceuticals Inc
|
445.77 | 112.43B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
616.18 | 64.09B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.00 | 54.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
149.55 | 31.57B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | ダウングレード | Jefferies | Buy → Hold |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2026-01-07 | 再開されました | Oppenheimer | Outperform |
| 2025-08-04 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-08-04 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 再開されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-03-31 | 開始されました | Redburn Atlantic | Buy |
| 2025-03-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-11-12 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-08-16 | アップグレード | Goldman | Neutral → Buy |
| 2024-02-16 | ダウングレード | Goldman | Buy → Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Equal Weight |
| 2023-10-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-05-05 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 開始されました | SMBC Nikko | Neutral |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Buy |
| 2022-09-09 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-06-07 | 開始されました | William Blair | Outperform |
| 2022-04-25 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 開始されました | Citigroup | Buy |
| 2022-02-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-01-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | アップグレード | Goldman | Neutral → Buy |
| 2021-11-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-10-04 | アップグレード | UBS | Neutral → Buy |
| 2021-08-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-02-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-02-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-01-25 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 再開されました | Berenberg | Hold |
| 2020-09-08 | 開始されました | Citigroup | Buy |
| 2020-08-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 再開されました | Evercore ISI | Outperform |
| 2020-03-19 | 開始されました | Berenberg | Buy |
| 2019-12-19 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-11-20 | 開始されました | Oppenheimer | Outperform |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-05-23 | 再開されました | Goldman | Neutral |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-03-05 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 開始されました | UBS | Neutral |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 繰り返されました | Stifel | Buy |
| 2018-08-07 | アップグレード | Stifel | Hold → Buy |
| 2018-05-04 | 繰り返されました | Stifel | Hold |
| 2018-03-28 | 開始されました | Evercore ISI | In-line |
すべてを表示
Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース
Alnylam Pharmaceuticals Unveils 2030 Targets, Betting on AMVUTTRA and Pipeline Readouts - Yahoo Finance
Alnylam to collaborate with Inceptive to use AI for RNAi therapy development - MSN
Alnylam Slides as Investors Refocus on Near-term Amvuttra Growth After Recent AI-deal Headlines - Moomoo
Bloom Energy, Astera Labs, Alnylam, Reddit could be among next adds to S&P 500 - MSN
Bloom Energy, Astera Labs, Alnylam, Reddit Could Be Among Next Adds to S&P 500 - Barron's
City banks nearly $100M for next-gen RNAi drugs - BioPharma Dive
Alnylam slides as investors refocus on near-term Amvuttra growth after recent AI-deal headlines - Quiver Quantitative
Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities - Seeking Alpha
The week in pharma: action, reaction and insight – week to June 5, 2026 - The Pharma Letter
How a US$2 Billion Generative AI RNAi Deal At Alnylam Pharmaceuticals (ALNY) Has Changed Its Investment Story - simplywall.st
H.C. Wainwright reiterates Alnylam stock Buy rating at $510 By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals (ALNY) Valuation Check As US$2b AI RNAi Collaboration With Inceptive Nucleics Gains Attention - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Partners with Inceptive Nucleics to Enhance Drug Discovery - GuruFocus
ALNY Reiterated by HC Wainwright & Co. -- Maintains Price Target at $510 - GuruFocus
Ionis, Alnylam, BioMarin up as Citi starts at buy on catalyst and growth outlook - MSN
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $510 - Moomoo
Alnylam Eyes Faster Drug Discovery With AI Partnership Worth Up To $2 Billion - Benzinga
Alnylam, Inceptive ink AI deal potentially worth $2B - BioPharma Dive
Alnylam Bets on AI for Speedy RNAi Drug Discovery and Development - Yahoo Finance
Alnylam, Inceptive Sign AI-RNAi Drug Discovery Deal Worth Up To $2bn - Citeline News & Insights
ATTR treatment landscape heats up as clinical progress gathers pace - The Pharma Letter
AI Collaboration Puts Alnylam’s RNAi Pipeline Productivity In Focus - simplywall.st
Alnylam signs $2 billion AI pact with Inceptive - The Pharma Letter
Alnylam (ALNY) Partners with Inceptive Nucleics for $2B Innovati - GuruFocus
Alnylam stock rises on $2B AI drug discovery partnership - Investing.com
Alnylam (ALNY) Partners with Inceptive Nucleics for $2B Innovation Deal - GuruFocus
Alnylam Pharmaceuticals (ALNY) Partners with Inceptive Nucleics for AI-Driven RNAi Development - GuruFocus
Alnylam and Inceptive Form Strategic AI Collaboration to Acceler - GuruFocus
Alnylam director Pyott sells $1.15m in stock By Investing.com - Investing.com Australia
Alnylam stock rises on $2B AI drug discovery partnership By Investing.com - Investing.com Nigeria
Alnylam director Pyott sells $1.15m in stock - Investing.com
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics - 01net
Alnylam, Inceptive sign up to $2 billion AI drug discovery deal - Reuters
Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeutics - statnews.com
Alnylam (ALNY) director sells 3,830 shares after expiring option exercise - Stock Titan
Alnylam Pharmaceuticals (ALNY) director receives 4,393 stock options grant - Stock Titan
Benjamin Cravatt joins ALNYLAM PHARMACEUTICALS (ALNY) board and files Form 3 - Stock Titan
Alnylam Pharmaceuticals stock hits 52-week low at $283.58 By Investing.com - Investing.com India
Homozygous Familial Hypercholesterolemia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Arrowhead Pharma, Novartis, Alnylam Pharma, LIB Therapeutics - Barchart.com
Alnylam Pharmaceuticals stock hits 52-week low at $283.58 - Investing.com
Alnylam Pharmaceuticals (ALNY): Company Profile, Stock Price, News, Rankings - Fortune
Avoiding Lag: Real-Time Signals in (ALNY) Movement - Stock Traders Daily
ALNY Stock Price, Quote & Chart | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
[144] ALNYLAM PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Are options traders betting on a big move in Alnylam stock? - MSN
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shows Strong Alignment with the Little Book That Makes You Rich Growth Strategy - ChartMill
Alnylam Pharmaceuticals (ALNY) Stock Analysis: A Biotech Powerhouse with 47.63% Potential Upside - DirectorsTalk Interviews
Are Options Traders Betting on a Big Move in Alnylam Stock? - TradingView
ALNY News | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) Adding Scientific Depth Amid RNAi Pipeline Scrutiny - simplywall.st
Alnylam Pharmaceuticals Inc (ALNY) 財務データ
収益
当期純利益
現金流量
EPS
0.71%
0.97%
大文字化:
|
ボリューム (24 時間):